Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30865951 | 0.88 | ALOX5 (0.72) | ALOX5ALDH1A1KMT2APOLBHPGD | |
| SCHEMBL13836513 | 0.86 | ALOX5 (0.72) | ALOX5ALDH1A1KMT2APOLBHPGD | |
| SCHEMBL12069952 | 0.84 | KMT2A (0.84) | ALOX5ALDH1A1KMT2APOLBMAPT | |
| SCHEMBL5235596 | 0.82 | LMNA (0.62) | ALOX5ALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL14859480 | 0.80 | ALDH1A1 (0.73) | ALOX5ALDH1A1KMT2APOLBMAPT | |
| SCHEMBL2153286 | 0.79 | ALOX5 (1.00) | ALOX5ALDH1A1KMT2APOLBMAPT | |
| SCHEMBL2153314 | 0.78 | ALDH1A1 (0.71) | ALOX5ALDH1A1KMT2APOLBHPGD | |
| SCHEMBL13836598 | 0.78 | ALOX5 (0.67) | ALOX5ALDH1A1KMT2APOLBMEN1 | |
| SCHEMBL12488830 | 0.78 | ALOX5 (0.71) | ALOX5ALDH1A1KMT2APOLB | |
| SCHEMBL2153249 | 0.76 | TDP1 (0.67) | ALOX5ALDH1A1KMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | ALOX5 2252/4885ALDH1A1 975/4885KMT2A 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.